CannaLean created CLC. It is a new form of cannabidiol (CBD) that has been associated with a substance called chitosan, for the treatment of dyslipidemia (abnormally high blood lipid content, or, in other words, high cholesterol). The results of the first preclinical research are very promising.
Does this mean that scientists could lower blood lipid levels?
CBD, a non-psychoactive compound in cannabis, is a known immunomodulator. It has been shown to improve metabolic functions. Therefore, it could play an important role in alleviating metabolic diseases. This would lead to a reduction in the fat content in the blood.
Chitosan is a biocompatible, non-toxic and non-immunogenic substance that generally binds to the non-polar portion of bile acid found in the intestines.
CLC is a new compound that has been formed from CBD and is associated with chitosan. This combination increases the potential use in reducing blood fats. Its main advantage is the purification of bile acid in a safe and non-aggressive way. This process lowers cholesterol.
Both components of this new molecule (CBD and proprietary chitosan particles) are separately considered safe for use. We know from previous research that they are very effective on their own. However, when combined, they provide much greater strength in lowering blood cholesterol and triglycerides.
Obesity and dyslipidemia are one of the main reasons why they die in the world. Previously, these were problems that occurred mostly in developed countries. But today they are becoming commonplace.
The World Health Organization (WHO) has released the terrible results of their studies:
- the prevalence of obesity nearly tripled between 1976 and 2016
- in 2016, over 1.9 billion adults over 18 were overweight; of these, 650 million (13% of the population) were obese
A worldwide study funded by the Bill and Melinda Gates Foundation revealed that about 4 million people die annually mainly from cardiovascular disease, diabetes, kidney disease and cancer.
About 300,000 deaths a year in America are attributed to obesity. It is associated with many other diseases to which these persons are more susceptible. Mortality is rapidly reduced in rich countries thanks to advanced and modern medicine that can keep high blood pressure and cardiovascular problems under control. Unfortunately, there are no such opportunities in developing countries.
Dr. Noah Ben Shalom, a leading chemist at CannaLean, holds a patent for chitosan-lecithin and has over 26 years of experience in polysaccharide polymer research. Together with Dr. Dror Robinson and Dr. Sari Prutchi Sagiva, under the leadership of David Bass, they teamed up and founded CannaLean in 2017.
In October 2017, a provisional patent was proposed, which included the use of CBD and chitosan to lower triglycerides and cholesterol in the blood, weight loss, and brought benefits of cardiovascular nature.
Despite all the hints available, there is still much to be explored.
Article by David Bassa (CannaLean Biotechs Ltd)
Article Source: healtheuropa.eu
Photo Source: pixabay.com (Mohammed Hassan, Gerd Altmann)